Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases

Pembrolizumab, a monoclonal antibody that binds to and inhibits the programmed cell death protein 1  receptor, belongs to the immune checkpoint inhibitor (ICI) class of cancer therapeutics. It is an effective second-line treatment for metastatic or advanced urothelial cancer [1]. However, ICIs including pembrolizumab are often associated with immune-related adverse events (irAEs), including pneum onitis, pancreatitis, dermatitis, myositis and nephritis. There are, however, few reports of nail toxicities following ICI treatment.

Source: European Journal of Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Yuriko Sugihara, Taketo Kawai, Daisuke Yamada, Chiaki Furuyama, Yusuke Sato, Haruki Kume Tags: Letter to the Editor Source Type: research